Atreca (FRA:0C1) Treasury Stock : €0.00 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Atreca Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Atreca's treasury stock for the quarter that ended in Sep. 2023 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Atreca Treasury Stock Historical Data

The historical data trend for Atreca's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Treasury Stock Chart

Atreca Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Treasury Stock

Get a 7-Day Free Trial

Atreca Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Atreca Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Atreca (FRA:0C1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (FRA:0C1) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

BCEL:USA 0C1:Germany

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.atreca.com

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Atreca (FRA:0C1) Headlines

No Headlines